Treatment | -log EC50 | |
---|---|---|
8-iso-PGE1 | 8-iso-PGE2 | |
M | ||
Vehicle | 6.53 ± 0.19 (9) | 6.89 ± 0.51 (6) |
AH 6809 (10 μM) | 6.67 ± 0.24 (9) | 7.27 ± 0.49 (6) |
Vehicle | 6.30 ± 0.13 (8) | 6.37 ± 0.16 (8) |
L-161, 982 (2 μM) | 6.11 ± 0.13 (8) | 6.27 ± 0.21 (8) |
AH 6809 | 6.48 ± 0.14 (8) | 6.58 ± 0.12 (7) |
AH 6809 + L-161,982 | 5.98 ± 0.11* (8) | 6.04 ± 0.09* (7) |
L-161,982 | 6.57 ± 0.11 (8) | 6.51 ± 0.11 (7) |
L-161,982 + AH 6809 | 5.98 ± 0.10* (8) | 6.13 ± 0.12* (7) |
↵* P < 0.05, significant difference in -log EC50 values with respect to vehicle or single antagonist-treated cells.